About this trial
This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.
Eligibility criteria
Qualifiers
Person aged 45 years or older at the time of signing the consent form.
Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer.
Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy).
Person aged 45 years or older at the time of signing the consent form.
Disqualifiers
History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years.
Patient diagnosed with lung cancer who has already started oncological treatment before sample collection.
Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago.
Patient who has undergone major surgery less than 7 days ago.
Trial design
Treatments tested in this trial
- Blood sample collection for telomere biomarker analysis
- Telomere biomarker analysis
Treatment groups
Sponsors and collaborators
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)
Lead sponsor
Life Length SL
Collaborator
Apices Soluciones S.L.
Collaborator